Applied Filters
Gilead hit with antitrust suit over HIV drugs
Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
California mulls state generics brand
California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
Judge refuses to block pay-for-delay law pending appeal
A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Senju, Bausch settle eye drop litigation against Indian generics maker
Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.
Fed Circuit issues mixed Sensipar verdict for Amgen
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.
Allergan agrees to pay $300m to end birth control litigation
Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.
Judge approves $120m Momenta and Sandoz settlement
A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
Generics makers appeal pay-for-delay ban to Ninth Circuit
A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.
Adamas settles Gocovri clash with Sandoz
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Eli Lilly secures Alimta patent win over Apotex
Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.
